LYNX-1: A Phase 3 Study of 0.75% Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbances

Study limitation reported by the research below: “The abstract does not report absolute letter-score changes in mLCVA — only the percentage of subjects who improved — which limits direct clinical interpretation of the magnitude of benefit.”